The European Union approved a new vaccine to prevent Ebola virus disease (Zaire ebolavirus species) in individuals aged 1 year and older. The vaccine consists of two components, Zabdeno (Ad26.ZEBOV) and Mvabea (MVA-BN-Filo). Zabdeno is given first and Mvabea is administered approximately eight weeks later as a booster.
Two treatments for Ebola which were undergoing trials in the Democratic Republic of Congo have been stopped early due to their success in treating Ebola. The two treatments will now be made widely available. One of the drugs is REGN-EB3, a cocktail of three monoclonal antibodies developed by Regeneron Pharmaceuticals. The other drug is mAb114, which is now being developed with Ridgeback Biotherapeutics.
A phase 1 randomized controlled trial found a Canadian Ebola vaccine was well-tolerated with no safety concerns.
Researchers say the next step is to begin developing therapies that target the delta peptide.
The vaccine, rVSV-ZEBOV, is not licensed but was shown to be highly protective against Ebola in clinical trials.
The development of GS-5734 creates a new therapeutic which provides protection filoviruses.
The treatment is made with horse antibodies and could be used in the next Ebola outbreak.
Using a new mouse model of early Ebola virus (EBOV) infection, US National Institutes of Health researchers have demonstrated how early immune system responses can affect development of EBOV disease.
The vaccine is only meant to be used to stop the spread of an existing outbreak.
The head of the Russian federal health and epidemic watchdog Rospotrebnadzor reported that a Russia-developed Ebola vaccine has successfully passed the second phase of clinical tests.